Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.99 Million USD | -7.57% |
| 2022 | 2.16 Million USD | 103.86% |
| 2021 | 1.06 Million USD | -95.52% |
| 2020 | 23.69 Million USD | 19.79% |
| 2019 | 19.78 Million USD | 42.52% |
| 2018 | 13.88 Million USD | 48.45% |
| 2017 | 9.35 Million USD | 902.11% |
| 2016 | -1.16 Million USD | 91.78% |
| 2015 | -14.17 Million USD | 18.47% |
| 2014 | -17.39 Million USD | -10.8% |
| 2013 | -15.69 Million USD | -1184.79% |
| 2012 | -1.22 Million USD | 84.15% |
| 2011 | -7.7 Million USD | 4.7% |
| 2010 | -8.08 Million USD | -149.79% |
| 2009 | -3.23 Million USD | -15.78% |
| 2008 | -2.79 Million USD | -693.45% |
| 2007 | -352.38 Thousand USD | -28.78% |
| 2006 | -273.63 Thousand USD | 95.44% |
| 2005 | -6 Million USD | -460.8% |
| 2004 | 1.66 Million USD | 64.47% |
| 2003 | 1.01 Million USD | 273.36% |
| 2002 | 270.82 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.45 Million USD | 24.06% |
| 2024 Q1 | 2.43 Million USD | 21.68% |
| 2023 FY | 1.99 Million USD | -7.57% |
| 2023 Q3 | 2.78 Million USD | 4.39% |
| 2023 Q2 | 2.67 Million USD | 2.51% |
| 2023 Q1 | 2.6 Million USD | 20.45% |
| 2023 Q4 | 1.99 Million USD | -28.29% |
| 2022 Q2 | 2.2 Million USD | 46.22% |
| 2022 FY | 2.16 Million USD | 103.86% |
| 2022 Q1 | 1.5 Million USD | 42.26% |
| 2022 Q4 | 2.16 Million USD | -18.48% |
| 2022 Q3 | 2.65 Million USD | 20.22% |
| 2021 Q1 | 24.54 Million USD | 3.59% |
| 2021 Q3 | 77.22 Thousand USD | -53.74% |
| 2021 FY | 1.06 Million USD | -95.52% |
| 2021 Q2 | 166.96 Thousand USD | -99.32% |
| 2021 Q4 | 1.06 Million USD | 1273.95% |
| 2020 Q1 | 20.44 Million USD | 3.32% |
| 2020 FY | 23.69 Million USD | 19.79% |
| 2020 Q2 | 21.38 Million USD | 4.64% |
| 2020 Q3 | 22.49 Million USD | 5.15% |
| 2020 Q4 | 23.69 Million USD | 5.37% |
| 2019 Q4 | 19.78 Million USD | 4.22% |
| 2019 Q3 | 18.98 Million USD | 7.24% |
| 2019 FY | 19.78 Million USD | 42.52% |
| 2019 Q1 | 16.22 Million USD | 16.89% |
| 2019 Q2 | 17.7 Million USD | 9.1% |
| 2018 Q3 | 13.13 Million USD | 7.35% |
| 2018 FY | 13.88 Million USD | 48.45% |
| 2018 Q4 | 13.88 Million USD | 5.72% |
| 2018 Q1 | 10.66 Million USD | 14.09% |
| 2018 Q2 | 12.23 Million USD | 14.66% |
| 2017 Q2 | 4.42 Million USD | 114.35% |
| 2017 Q1 | 2.06 Million USD | 276.97% |
| 2017 Q3 | 6.89 Million USD | 55.84% |
| 2017 FY | 9.35 Million USD | 902.11% |
| 2017 Q4 | 9.35 Million USD | 35.68% |
| 2016 FY | -1.16 Million USD | 91.78% |
| 2016 Q4 | -1.16 Million USD | 77.49% |
| 2016 Q3 | -5.17 Million USD | -5.86% |
| 2016 Q1 | -9.76 Million USD | 31.16% |
| 2016 Q2 | -4.89 Million USD | 49.89% |
| 2015 Q2 | -23.11 Million USD | -63.13% |
| 2015 FY | -14.17 Million USD | 18.47% |
| 2015 Q4 | -14.17 Million USD | 24.91% |
| 2015 Q3 | -18.88 Million USD | 18.31% |
| 2015 Q1 | -14.17 Million USD | 18.52% |
| 2014 Q2 | -18.12 Million USD | -8.87% |
| 2014 FY | -17.39 Million USD | -10.8% |
| 2014 Q1 | -16.64 Million USD | -6.07% |
| 2014 Q4 | -17.39 Million USD | 2.15% |
| 2014 Q3 | -17.77 Million USD | 1.94% |
| 2013 FY | -15.69 Million USD | -1184.79% |
| 2013 Q4 | -15.69 Million USD | -90.17% |
| 2013 Q3 | -8.25 Million USD | -78.03% |
| 2013 Q2 | -4.63 Million USD | -7.36% |
| 2013 Q1 | -4.31 Million USD | -253.45% |
| 2012 Q3 | -1.84 Million USD | 54.76% |
| 2012 FY | -1.22 Million USD | 84.15% |
| 2012 Q4 | -1.22 Million USD | 33.68% |
| 2012 Q1 | -4.9 Million USD | 36.41% |
| 2012 Q2 | -4.07 Million USD | 16.91% |
| 2011 Q2 | -14.39 Million USD | -16.04% |
| 2011 Q3 | -10.81 Million USD | 24.86% |
| 2011 FY | -7.7 Million USD | 4.7% |
| 2011 Q4 | -7.7 Million USD | 28.73% |
| 2011 Q1 | -12.4 Million USD | -53.35% |
| 2010 Q1 | -11.44 Million USD | -253.42% |
| 2010 FY | -8.08 Million USD | -149.79% |
| 2010 Q4 | -8.08 Million USD | 19.5% |
| 2010 Q3 | -10.04 Million USD | 19.7% |
| 2010 Q2 | -12.5 Million USD | -9.33% |
| 2009 Q1 | -1.49 Million USD | 46.4% |
| 2009 FY | -3.23 Million USD | -15.78% |
| 2009 Q4 | -3.23 Million USD | 14.37% |
| 2009 Q3 | -3.78 Million USD | 0.85% |
| 2009 Q2 | -3.81 Million USD | -154.42% |
| 2008 Q2 | -5169.00 USD | 97.58% |
| 2008 FY | -2.79 Million USD | -693.45% |
| 2008 Q1 | -213.36 Thousand USD | 39.45% |
| 2008 Q4 | -2.79 Million USD | -522.99% |
| 2008 Q3 | -448.8 Thousand USD | -8582.67% |
| 2007 Q4 | -352.38 Thousand USD | -3.96% |
| 2007 Q2 | -232.91 Thousand USD | 46.8% |
| 2007 Q1 | -437.78 Thousand USD | -59.99% |
| 2007 Q3 | -338.95 Thousand USD | -45.53% |
| 2007 FY | -352.38 Thousand USD | -28.78% |
| 2006 Q2 | -735.54 Thousand USD | 75.06% |
| 2006 Q1 | -2.94 Million USD | 50.84% |
| 2006 FY | -273.63 Thousand USD | 95.44% |
| 2006 Q4 | -273.63 Thousand USD | 73.35% |
| 2006 Q3 | -1.02 Million USD | -39.59% |
| 2005 Q3 | 1.2 Million USD | -13.31% |
| 2005 Q4 | -6 Million USD | -597.79% |
| 2005 FY | -6 Million USD | -460.8% |
| 2005 Q1 | 1.68 Million USD | 1.19% |
| 2005 Q2 | 1.39 Million USD | -17.38% |
| 2004 Q4 | 1.66 Million USD | 28.38% |
| 2004 Q3 | 1.29 Million USD | -5.67% |
| 2004 Q1 | 863.19 Thousand USD | -14.63% |
| 2004 Q2 | 1.37 Million USD | 59.08% |
| 2004 FY | 1.66 Million USD | 64.47% |
| 2003 FY | 1.01 Million USD | 273.36% |
| 2003 Q4 | 1.01 Million USD | -7.21% |
| 2003 Q3 | 1.08 Million USD | 7.81% |
| 2003 Q2 | 1.01 Million USD | 13.58% |
| 2003 Q1 | 889.92 Thousand USD | 228.6% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 270.82 Thousand USD | 0.0% |
| 2002 Q3 | 5599.00 USD | 21.01% |
| 2002 Q2 | 4627.00 USD | 0.0% |
| 2002 Q4 | 270.82 Thousand USD | 4736.99% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | 2100.00 USD | -38.24% |
| 2001 Q3 | 3400.00 USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 152725.344% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 64.602% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 95.328% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 900.974% |
| Rebus Holdings, Inc. | 305 Thousand USD | -555.538% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 131.714% |
| Qrons Inc. | 351.42 Thousand USD | -468.935% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -221.258% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 95.397% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 9897.099% |
| Skye Bioscience, Inc. | -5.72 Million USD | 134.946% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 87.316% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 51.448% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -397.548% |
| SQZ Biotechnologies Company | -36.23 Million USD | 105.517% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 10.83% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -115.641% |
| Mesoblast Limited | 55.85 Million USD | 96.421% |
| Marizyme, Inc. | 18.56 Million USD | 89.233% |
| Genus plc | 190.6 Million USD | 98.951% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 10.575% |
| Pharming Group N.V. | 109.8 Million USD | 98.179% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -132.422% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -64.71% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -194.028% |
| ContraFect Corporation | -6.02 Million USD | 133.179% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1385.002% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -73.043% |
| IMV Inc. | 7.67 Million USD | 73.934% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 63.66% |
| MultiCell Technologies, Inc. | 90.04 USD | -2220459.751% |
| ONE Bio Corp. | 9.04 Million USD | 77.883% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 372.405% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 84.556% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -46.157% |
| Q BioMed Inc. | 4.06 Million USD | 50.754% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 93.456% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -98.408% |
| Biomind Labs Inc. | 711.4 Thousand USD | -181.05% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.698% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 84.388% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -455.834% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1330.139% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -9963.885% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 9.2% |
| GB Sciences, Inc. | 1.74 Million USD | -14.426% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1187.88% |
| HST Global, Inc. | 96.79 Thousand USD | -1965.637% |
| CSL Limited | 10.52 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -869.557% |
| Halberd Corporation | 144.72 Thousand USD | -1281.549% |
| Enzolytics Inc. | 981.65 Thousand USD | -103.675% |
| Agentix Corp. | 37.63 Thousand USD | -5213.151% |
| Resverlogix Corp. | 6.45 Million USD | 69.006% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 397.047% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.099% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.253% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 71.724% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 26.184% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 122.618% |
| AVAX Technologies, Inc. | -5.9 Million USD | 133.87% |
| Zenith Capital Corp. | 10.06 Thousand USD | -19766.773% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.188% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -897.541% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 16.204% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1115.369% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 11014.903% |
| Kadimastem Ltd | -253.1 Thousand USD | 889.955% |
| Helix BioMedix, Inc. | -2.57 Million USD | 177.796% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 90.139% |
| BioStem Technologies, Inc. | 4.47 Million USD | 55.291% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -893.467% |
| LadRx Corporation | -2.03 Million USD | 198.179% |
| Cell Source, Inc. | 9.23 Million USD | 78.343% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -214.782% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -214.782% |
| NovAccess Global Inc. | 2.17 Million USD | 8.22% |
| Affymax, Inc. | -5.59 Million USD | 135.723% |
| Itoco Inc. | 228.3 Thousand USD | -775.755% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1370.26% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 59.665% |
| Mobile Lads Corp. | 484.23 Thousand USD | -312.9% |
| CytoDyn Inc. | 20.26 Million USD | 90.132% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 309125.039% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 21672.277% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 74.054% |
| SYBLEU INC | 473.71 Thousand USD | -322.067% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 55.141% |
| International Stem Cell Corporation | 2.59 Million USD | 22.803% |
| Bioxytran, Inc. | 1.89 Million USD | -5.291% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3103.486% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 8.323% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 41.777% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 76.624% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -158.785% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 259.951% |
| Neutra Corp. | 52.18 Thousand USD | -3731.207% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 180.329% |
| PureTech Health plc | -167.19 Million USD | 101.196% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 916.385% |
| IXICO plc | -4.44 Million USD | 144.985% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 84.875% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.355% |
| CSL Limited | 10.52 Billion USD | 99.981% |
| Cellectis S.A. | -43.81 Million USD | 104.563% |